Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Amgen Inc | 144 |
| 2 | Infinity Pharmaceuticals Inc | 111 |
| 3 | Revolution Medicines Inc | 104 |
| 4 | University of Michigan (System) | 63 |
| 5 | Kura Oncology Inc | 52 |
| 6 | Merck and Co Inc | 46 |
| 7 | Takeda Pharmaceutical Co Ltd | 45 |
| 8 | Roche Holding AG | 41 |
| 9 | Sony Group Corp | 30 |
| 10 | Sumitomo Chemical Co Ltd | 27 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 1,207 |
| 2 | A61K | Medicinal preparations | 1,082 |
| 3 | C07D | Heterocyclic compounds | 893 |
| 4 | C07K | Peptides | 259 |
| 5 | C07B | General methods of organic chemistry | 160 |
| 6 | C07F | Organometallic compounds | 138 |
| 7 | Y02A | Climate change adaptation | 120 |
| 8 | G01N | Investigating / analysing materials | 83 |
| 9 | C12N | Microorganisms, enzymes | 80 |
| 10 | C12Q | Measuring/testing involving enzymes | 56 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| 4-Imino-1,3-diazabicyclo-(3.1.0)-hexan-2-one as a cancerostat and immuno-stimulant | 1978 | Roche Holding AG | 14 |
| Use of imexon as an immune suppressive and pharmaceutical compositions containing imexon | 1994 | Roche Holding AG | 7 |
| Use of imexone as an immunosuppressive agent | 1990 | Roche Holding AG | 2 |
| Use of imexon as immunosuppressant | 1990 | 2 | |
| PROCESS FOR PRODUCING IMMUNOSUPPRESSIVE PHARMACEUTICAL COMPOSITIONS COMPRISING IMEXON | 1990 | 0 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2017 | 1 |
| 2019 | 4 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 3 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Robert T. Dorr | University of Arizona | 20 |
| 2 | Betty K. Samulitis | University of Arizona | 9 |
| 3 | Evan M. Hersh | University of Arizona | 9 |
| 4 | Terry H. Landowski | University of Arizona | 9 |
| 5 | Anton Simeonov | National Center for Advancing Translational Sciences | 5 |
| 6 | Kevin M. Okleberry | Utah State University | 4 |
| 7 | Claire M. Payne | University of Arizona | 4 |
| 8 | John D. Morrey | Utah State University | 4 |
| 9 | Margaret E. Tome | University of Arizona | 4 |
| 10 | Ajit Jadhav | National Center for Advancing Translational Sciences | 4 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Redox-Directed Cancer Therapeutics: Molecular Mechanisms and Opportunities | 2009 | 459 | Retinoids in leukemia and cellular processes |
| Induction of mitochondrial changes in myeloma cells by imexon | 2001 | 92 | Drug Transport and Resistance Mechanisms |
| Induction of oxidative stress and apoptosis in myeloma cells by the aziridine-containing agent imexon | 2000 | 90 | Synthesis and Catalytic Reactions |
| Phase I Trial of Imexon in Patients With Advanced Malignancy | 2007 | 56 | Synthesis and biological activity |
| Imexon-Induced Apoptosis in Multiple Myeloma Tumor Cells Is Caspase-8 Dependent | 2004 | 54 | Drug Transport and Resistance Mechanisms |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of Imexon?
Which organizations hold the most patents for Imexon?
What are the key research topics associated with Imexon in published literature?
How has patent activity for Imexon evolved over recent years?
What are the primary CPC patent classifications for Imexon-related inventions?